StreetInsider.com News Articles

BTIG survey finds GLP-1 users cut 500 calories daily from diet

Thu, 01 Oct 2026 06:51:59 -0400

Investing.com - A new survey from BTIG shows adoption of GLP-1 weight-loss medications continues to expand among lower-income and younger users, with most consumers reducing their daily caloric intake by approximately 500 calories. The firm conducted its third semiannual survey of 1,000 GLP-1 users to track demographics, usage patterns and eating habits.

The survey found 51% of GLP-1 users earn less than $50,000 annually, up from 34% in September 2025, while users under 35 years old increased to 35% from 26% over the same period. Users aged 65 and older declined to 5% from 14%. Middle-age users between 35 and 64

BTIG survey finds GLP-1 users cut 500 calories daily from diet

Thu, 01 Oct 2026 06:51:59 -0400

Novo Nordisk Wegovy data shows liver fat reduction in obesity trial

Thu, 01 Oct 2026 06:48:34 -0400

Novo Nordisk (NYSE: NVO) presented a post hoc analysis from a sub-population of its STEP UP trial showing that Wegovy reduced liver fat in adults with obesity who do not have diabetes, according to data presented at the European Association for the Study of Diabetes Annual Meeting in Milan, Italy.

The analysis included 55 participants and measured liver fat using magnetic resonance imaging. Mean liver fat in the semaglutide group declined from 8.8% at baseline to 3.1% at week 72. Of the 26 participants who began the trial with liver fat above 5%, 88.5%, or 23 participants, reached below the 5%

Novo Nordisk Wegovy data shows liver fat reduction in obesity trial

Thu, 01 Oct 2026 06:48:34 -0400

Novo Nordisk Wegovy data shows liver fat reduction in obesity trial

Thu, 01 Oct 2026 06:48:34 -0400

Novo Nordisk shares new CagriSema brain and metabolic study data

Wed, 30 Sep 2026 08:44:37 -0400

Novo Nordisk (NYSE: NVO) presented new clinical data on its investigational drug CagriSema at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, covering brain activity, fat distribution, and bone health across three separate studies.

In a 52-week functional MRI study involving adults with overweight or obesity, CagriSema was associated with changes in brain responses to high-calorie food cues in regions linked to cravings, reward, sensory processing, and behavioral control. Participants also reported reductions in hunger, appetite, and food-related thoughts. The study recorded a 22.4% reduction in body weight versus placebo at 52 weeks. The study received a

Novo Nordisk shares new CagriSema brain and metabolic study data

Wed, 30 Sep 2026 08:44:37 -0400

Novo Nordisk shares new CagriSema brain and metabolic study data

Wed, 30 Sep 2026 08:44:37 -0400

Novo Nordisk study shows weight loss in patients switching to oral Wegovy

Wed, 30 Sep 2026 06:03:30 -0400

Novo Nordisk (NYSE: NVO) released real-world data from the OCTANE study showing that adults with overweight or obesity who switched from injectable GLP-1 medicines to once-daily oral semaglutide, marketed as the Wegovy pill, lost an average of 4.1%, or 8.8 lbs, over three months, based on an average starting weight of 221.6 lbs.

The study analyzed de-identified data from the Ro telehealth platform and was presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy, on September 30, 2026.

Participants had previously used either tirzepatide or semaglutide injections for weight management before switching to

Novo Nordisk study shows weight loss in patients switching to oral Wegovy

Wed, 30 Sep 2026 06:03:30 -0400

Participants had previously used either tirzepatide or semaglutide injections for weight management before switching to

BMO Capital Reiterates Market Perform Rating on Novo Nordisk (NVO)

Tue, 29 Sep 2026 09:35:49 -0400

BMO Capital analyst Evan Seigerman reiterated a Market Perform rating and $47.00 price target on Novo Nordisk (NYSE: NVO).

The analyst commented: "Novo Adds a Once-Weekly Oral Incretin Option w/ Hengrui Deal; We are kicking off EASD day 2 with a Novo deal announcement, the company highlighting in today's release plan's to license Hengrui’s HRS-1596, a Ph 1-ready GLP-1/GIP dual agonist peptide with the potential for once-weekly oral dosing. Not the transformative deal some may have been looking for, HRS-1596 remains early, and the deal is unlikely to alter near-term competitive dynamics. Still, HRS-1596 could provide an attractive longer-term pipeline option

Novo Nordisk licenses oral GLP-1/GIP dual agonist from Hengrui Pharma

Tue, 29 Sep 2026 06:05:30 -0400

Novo Nordisk (NYSE: NVO) has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready drug candidate designed as a dual agonist targeting GLP-1 and GIP receptors, with potential for once-weekly oral dosing.

Under the agreement, Novo Nordisk will receive exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao, and Taiwan. The deal includes a $300 million upfront payment, with total potential value reaching up to $2.6 billion, contingent on development, regulatory, and commercial milestones. Hengrui Pharma is also eligible to receive royalties based on net sales within the licensed

Novo Nordisk licenses oral GLP-1/GIP dual agonist from Hengrui Pharma

Tue, 29 Sep 2026 06:05:30 -0400

Novo Nordisk licenses oral GLP-1/GIP dual agonist from Hengrui Pharma

Tue, 29 Sep 2026 06:05:30 -0400

Novo Nordisk study links semaglutide 2 mg to lower heart risk vs tirzepatide

Tue, 29 Sep 2026 06:04:45 -0400

Novo Nordisk (NYSE: NVO) presented new retrospective real-world evidence at the European Association for the Study of Diabetes Annual Meeting 2026 in Milan, Italy, comparing cardiovascular outcomes in adults with type 2 diabetes who escalated their semaglutide dose versus those who switched to tirzepatide.

The analysis of 636,525 adults initially treated with once-weekly semaglutide injection 1 mg found that patients who escalated to semaglutide 2 mg had a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) — including all-cause death, heart attack, and stroke — compared with those who switched to tirzepatide at doses up to 15 mg

Novo Nordisk study links semaglutide 2 mg to lower heart risk vs tirzepatide

Tue, 29 Sep 2026 06:04:45 -0400

Novo Nordisk study links semaglutide 2 mg to lower heart risk vs tirzepatide

Tue, 29 Sep 2026 06:04:45 -0400

Form 6-K NOVO NORDISK A S For: Sep 28

Mon, 28 Sep 2026 11:24:00 -0400

si-local-file:///var/storage/secattach/20260928/27111964.html

CMS pumps $51M into rural Texas to fight diabetes and obesity

Mon, 28 Sep 2026 10:10:24 -0400

Investing.com - The federal government is deploying $51 million to 68 rural Texas hospital districts to build and expand chronic disease prevention programs targeting diabetes, cardiovascular disease, respiratory illness, and obesity, according to a CMS announcement dated September 28, 2026. The funding is the first visible tranche of Texas's $281 million first-year allocation from the $50 billion Rural Health Transformation Program (RHTP), itself established by the Working Families Tax Cuts Act.